Suzetrigine Phase 3 Trial for Cardiac and Bariatric Surgery Patients NCT07539623

NIH registered a new Phase 3 clinical trial (NCT07539623) on ClinicalTrials.gov. The trial will enroll participants undergoing bariatric weight-loss surgery and cardiac sternotomy procedures, randomizing them to receive Suzetrigine or placebo in addition to established multimodal opioid-sparing pain management protocols. The primary endpoints are post-operative opioid consumption and pain scores.

Affected parties include clinical trial sponsors, contract research organizations, and clinical investigators conducting or monitoring pain-management studies in surgical populations. This registry entry establishes the formal trial parameters and will be updated with recruitment status and results as the study progresses. No compliance obligations or regulatory approvals are created by this registration notice.